Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C156698
http://purl.obolibrary.org/obo/NCIT_C156698
|
|---|---|
| Preferred Name | Rhenium Re-188 Etidronate |
| Definitions |
A synthetic compound containing the bisphosphonate etidronate (hydroxyethylidene diphosphonate, HEDP) labeled with rhenium Re188, a beta-emitting radioisotope with potential antineoplastic activity. Upon administration, Re-188 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. The beta-radiation may provide localized anti-tumor radiotoxicity while sparing extramedullary bone marrow tissues.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic compound containing the bisphosphonate etidronate (hydroxyethylidene diphosphonate, HEDP) labeled with rhenium Re188, a beta-emitting radioisotope with potential antineoplastic activity. Upon administration, Re-188 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. The beta-radiation may provide localized anti-tumor radiotoxicity while sparing extramedullary bone marrow tissues. |
|---|---|
| prefLabel | Rhenium Re-188 Etidronate
|
| label | Rhenium Re-188 Etidronate
|
| NCI_META_CUI | CL935713
|
| PDQ_Closed_Trial_Search_ID | 795714
|
| code | C156698
|
| prefixIRI | NCIT:C156698
|
| in_subset | |
| Preferred_Name | Rhenium Re-188 Etidronate
|
| FDA_UNII_Code | XWW2JNQ850
|
| Contributing_Source | FDA
|
| Maps_To | Rhenium Re-188 Etidronate
|
| NCI_Drug_Dictionary_ID | 795714
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 795714
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |